Need professional-grade analysis? Visit stockanalysis.com
$1.04B
N/A
N/A
N/A
Xeris Pharmaceuticals Inc (XERS) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $6.37, up 4.08% from the previous close.
Over the past year, XERS has traded between a low of $4.10 and a high of $9.90. The stock has gained 55.4% over this period. It is currently 35.7% below its 52-week high.
Xeris Pharmaceuticals Inc has a market capitalization of $1.04B.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Side-by-side comparison against top Healthcare peers.